Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG06466 for Spasticity in Multiple Sclerosis
NCT04990219Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in Spasticity comparing Lu AG06466 with Placebo (2 arms). Primary endpoints: Number of Participants with Spasticity Response at 5 weeks and Change from Baseline to Week 5 in Spasticity Numerical Rating Scale Score. Started Sep 2021; status: terminated.
02
Drugs
ABX-1431
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT04990219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990219.